RecruitingPhase 1/2

LYell SYndrome MEsenchymal Stromal Cells Treatment

France15 participantsStarted 2024-04-15

Plain-language summary

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare severe cutaneous adverse reactions (SCARs) to drugs. To date, no curative drug has demonstrated with a good level of evidence its ability to promote SJS and TEN healing and could contribute to earlier reepithelialisation. Mesenchymal stroma cells (MSCs) therapy represents a new therapeutic approach. eg, in patients with cardiovascular diseases, neurological diseases, renal transplantation, lung diseases as acute respiratory distress syndrome. Recently, MSCs have been proposed in both burn wound healing with a significantly decrease of the unhealed burn area and in cutaneous radiation. Moreover, MSCs have immunomodulation properties potentially effective in refractory acute and chronic graft versus host disease (GVHD) by improving thymic function and induction of Tregs. Indeed, MSCs are able to migrate to inflamed tissues after stimulation by pro-inflammatory cytokines and to modulate the local inflammatory reactions. MSCs have also demonstrated their ability to promote tissue remodelling, angiogenesis and immunomodulation through either differentiation or secretion of several growth factors such as VEGF, basic FGF and various cytokines. Therefore, combining their immunomodulation effect and secretion of soluble factors involved in wound repair, MSCs might be valuable as a cell therapy strategy for promoting cutaneous healing in SJS-TEN syndrome and subsequently decrease the morbi-mortality.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients ≥ 18 and ≤ 75 years-old * Admission ≤ 10 days after the index date (date of the first symptoms of the disease) * Patient with confirmed SJS-TEN diagnosis hospitalized in the department of Dermatology or intensive care medicine * At least 10 % of detachable-detached body surface area at any time during the first 10 days after the index date (date of the first symptoms of the disease) * Who, after the nature of the study has been explained to them or a support person (if applicable), and prior to any protocol specific procedures being performed, have given written consent according to local regulatory requirements * Affiliated to a social security scheme Exclusion Criteria: * Pregnant or breastfeeding women * History of malignant disease within the past ten years and or presence of metastasis * Positive serology for HIV * Active infection for hepatitis B or C * Detection of Coronavirus SARS CoV-2 RNA on admission (positive RT-PCR), if performed in the usual care * Decompensated cardiac failure * Uncontrolled epilepsia * Previous history of allogenic bone marrow transplantation * Participation in other interventional drug research Patient deprived of liberty by a judicial or administrative decision or under the protection of justice * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the research protocol and follow-up schedule * Patient under tutorship or curatorship * Patient under psychi…

What they're measuring

Safety : Observation of at least one adverse effect

Timeframe: Day 10

Efficacy : Rate of complete or almost complete reepithelialisation

Timeframe: Day 7 after infusion

Trial details

NCT IDNCT04711200

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-04

Contact for this trial

Saskia Oro, MD

0149812536 saskia.oro@aphp.fr